Abstract
Background Schools have been closed in the Philippines since March 2020 due to the COVID-19 pandemic. In September 2021, the government already allowed a pilot run of limited in-person classes in low-risk areas around the country, in the face of the continuing threat of the virus.
Objective We aim to assess which regions in the Philippines can already reopen their schools.
Methods In this study, we simulate school reopening scenarios with our modified COVID-19 agent-based model for the seventeen regions of the country. We tested different vaccination coverages and calculated the coverage at which deaths and infections would begin to show a downtick. The School Reopening Viability (SRV) of a region is then determined by getting the difference between the current vaccination coverage (as of 13 February 2022) and the downtick in infection or death.
Results The recent data on the COVID-19 Omicron variant transmission shows that all regions except Regions 7, 9, and BARMM can reopen. Comparing the SRV of a region to its vaccination progress, we see that those with high vaccination rates are the ones most viable for school reopening, as in the case of regions in Luzon. On the other hand, those with low vaccination rates are the ones that would need to ramp up their vaccination efforts before reopening their schools.
Conclusions We recommend that with the current vaccination coverages for the regions, all regions except Regions 7, 9, and BARMM may undergo school reopening. Alongside efforts to reopen schools, vaccination efforts should still be continued and ramped up, especially in the regions of interest. Policymakers may take insights from this study.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study did not receive any funding. Earlier studies (April-June, 2020) were funded by the UP Alumni Engineers.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
https://doh.gov.ph/covid-19/case-tracker. Accessed 30 March 2022.
https://www.rappler.com/newsbreak/data-documents/tracker-covid-19-vaccines-distribution-philippines. Accessed 1 March 2022.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Email: (vabongolan{at}up.edu.ph, ngfrancisco{at}up.edu.ph, mdsaliba{at}up.edu.ph, jnceleste{at}up.edu.ph)
Data Availability
All data used in our simulations are available online. Our mathematical model has been well-described in previous publications. Our agent-based model is proprietary.
https://doh.gov.ph/covid-19/case-tracker
https://www.rappler.com/newsbreak/data-documents/tracker-covid-19-vaccines-distribution-philippines
